Akebia Therapeutics Inc. (NASDAQ:AKBA) does about 3.14M shares in volume on a normal day but saw 1312829 shares change hands in the recent trading day. The company now has a market cap of 257.81M USD. Its current market price is $1.23, marking an increase of 3.80% compared to the previous close of $1.18. The 52 week high reached by this stock is $2.48 whilst the lowest price level in 52 weeks is $0.78. The script in recent trading has seen the stock touch a high of $7 and a low of $6.
Akebia Therapeutics Inc. (AKBA) has a 20-day trading average at $1.3398 and the current price is -50.40% off the 52-week high compared with 57.67% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.1522 and its 200-day simple moving average is $1.2960. If we look at the stock’s price movements over the week, volatility stands at 7.18%, which increases to 8.56% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.98 to suggest the stock is neutral.
The consensus objective for the share price is $4.50, suggesting that the stock has a potential upside of 72.67% over the period. The median price target is 81.08% away from the current levels at $6.5.
4 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 29, 2023 when BTIG Research resumed the stock to “Buy” and issued a price target of $4. H.C. Wainwright upgraded the stock to “Buy” from Neutral on August 28, 2023 at a price target of $3.75. Piper Sandler upgraded its price target at $2-$4.
Akebia Therapeutics Inc. (AKBA) stock is down -10.22% over the week and 29.75% over the past month. Its price is -0.81% year-to-date and -24.07% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.05 and -0.26 for whole year. Expected sales for next quarter are $44.71M, which analysts say will come at $172.53M for the current fiscal year and next year at $159.38M. In addition, estimates put the company’s current quarterly revenue at an average of $49.45M.
Its 12-month price target is $6.5. To reach the target analysts have set, the stock logically needs to grow 72.67 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $6, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $7.
The company has a return on investment of -67.22% and return on equity of -554.87%. The beta has a value of 0.81. Price to sales ratio is 1.38.
